Kingsway Pharmaceuticals has acquired a strategic minority equity stake in CIGA Healthcare, a global diagnostics provider. This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market.
The investment creates a joint venture alignment between the two companies, fortifying Kingsway’s supply chain reliability and widening its pipeline of branded and private label diagnostic offerings for major U.S. retailers. Kingsway, which owns national brands including Blue-Emu®, Bikini Zone, PBZ OTC, and EPT, has been expanding its presence in private label healthcare and secured two major retailer partnerships in 2025.
Based in the United Kingdom with global reach across more than 70 countries, CIGA Healthcare provides one of the broadest portfolios of rapid tests and home diagnostic technologies for consumers, healthcare systems, governments, and retail partners. Its portfolio spans pregnancy and fertility, women’s health, UTI and infection screening, menopause testing, respiratory and allergy categories, veterinary diagnostics, and glucose monitoring solutions.
The new equity partnership enables Kingsway to streamline manufacturing, accelerate speed-to-market, and broaden its diagnostic lineup through both retailer private label offerings and future Kingsway-branded diagnostic products. For CIGA Healthcare, the relationship opens new U.S. retail channels supported by Kingsway’s consumer brand expertise and its relationships across the national retail landscape.
Kingsway stated that the partnership reflects a commitment to improving consumer access to trustworthy health tools and reinforcing the role of diagnostics in at-home health decision-making. Both companies expect the collaboration to accelerate category innovation and expand testing availability across new markets and channels.
KEY QUOTES
“For us, this is more than expansion, it’s stewardship. Families deserve confidence, clarity, and access when it comes to their health. By partnering with CIGA Healthcare, we are securing a faster, more stable supply path for diagnostics in the U.S. while also expanding the innovation we can bring to retailers and consumers. We see diagnostics as a category that empowers households to make informed health decisions at home, and we are committed to leading in that space with integrity and impact.”
Benjamin Blessing, COO, Kingsway Pharmaceuticals
“We are delighted to partner with Kingsway Pharmaceuticals. Their retail relationships, consumer brand-building expertise, and strong U.S. market understanding complement our global diagnostics platform. Together, we will accelerate access to diagnostic testing across new categories, new markets, and new channels.”
Irwin Armstrong, CEO, CIGA Healthcare
